Boosting Glioblastoma Therapy with Targeted Pyroptosis Induction

dc.contributor.authorFang Xinggang
dc.contributor.authorChen Zhuo
dc.contributor.authorZhou Wenhui
dc.contributor.authorLi Tongfei
dc.contributor.authorWang Man
dc.contributor.authorGao Yujiu
dc.contributor.authorMa Shinan
dc.contributor.authorFeng Ying
dc.contributor.authorDu Shiming
dc.contributor.authorLan Peimin
dc.contributor.authorChen Hanyu
dc.contributor.authorWei Jiarui
dc.contributor.authorZhang Sisi
dc.contributor.authorLi Zixiang
dc.contributor.authorLiu Xinglin
dc.contributor.authorZhang Hongbo
dc.contributor.authorGuo Xingrong
dc.contributor.authorLuo Jie
dc.contributor.organizationfi=Turun biotiedekeskus|en=Turku Bioscience Centre|
dc.contributor.organization-code1.2.246.10.2458963.20.18586209670
dc.converis.publication-id179489211
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/179489211
dc.date.accessioned2025-08-28T01:58:35Z
dc.date.available2025-08-28T01:58:35Z
dc.description.abstract<p>Glioblastoma (GBM) is a highly aggressive cancer that currently lacks effective treatments. Pyroptosis has emerged as a promising therapeutic approach for cancer, but there is still a need for new pyroptosis boosters to target cancer cells. In this study, it is reported that Aloe-emodin (AE), a natural compound derived from plants, can inhibit GBM cells by inducing pyroptosis, making it a potential booster for pyroptosis-mediated GBM therapy. However, administering AE is challenging due to the blood-brain barrier (BBB) and its non-selectivity. To overcome this obstacle, AE@ZIF-8 NPs are developed, a biomineralized nanocarrier that releases AE in response to the tumor's acidic microenvironment (TAM). Further modification of the nanocarrier with transferrin (Tf) and polyethylene glycol-poly (lactic-co-glycolic acid) (PEG-PLGA) improves its penetration through the BBB and tumor targeting, respectively. The results show that AE-NPs (Tf-PEG-PLGA modified AE@ZIF-8 NPs) significantly increase the intracranial distribution and tumor tissue accumulation, enhancing GBM pyroptosis. Additionally, AE-NPs activate antitumor immunity and reduce AE-related toxicity. Overall, this study provides a new approach for GBM therapy and offers a nanocarrier that is capable of penetrating the BBB, targeting tumors, and attenuating toxicity.<br></p>
dc.identifier.eissn1613-6829
dc.identifier.jour-issn1613-6810
dc.identifier.olddbid208372
dc.identifier.oldhandle10024/191399
dc.identifier.urihttps://www.utupub.fi/handle/11111/57794
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/10.1002/smll.202207604
dc.identifier.urnURN:NBN:fi-fe2023051644555
dc.language.isoen
dc.okm.affiliatedauthorZhang, Hongbo
dc.okm.discipline318 Medical biotechnologyen_GB
dc.okm.discipline318 Lääketieteen bioteknologiafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherWILEY-V C H VERLAG GMBH
dc.publisher.countryGermanyen_GB
dc.publisher.countrySaksafi_FI
dc.publisher.country-codeDE
dc.relation.doi10.1002/smll.202207604
dc.relation.ispartofjournalSmall
dc.source.identifierhttps://www.utupub.fi/handle/10024/191399
dc.titleBoosting Glioblastoma Therapy with Targeted Pyroptosis Induction
dc.year.issued2023

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
ZhangHongboEtAl2023BoostingGlioblastomaTherapy.pdf
Size:
12.83 MB
Format:
Adobe Portable Document Format